

SAFETY DATA SHEET

Date of Original Issue: 30AUG2012

Revision Number: 3

Revision Date: 29JAN2024

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name: Voriconazole for Injection

1.2. Relevant identified uses of the substance or mixture and uses advised against

Product Use: Pharmaceutical product used as anti-infective agent

Synonyms: Voriconazole

1.3. Details of the supplier of the safety data sheet

Manufacturer

Gland Pharmaceuticals
Survey No. 143-148, 150 & 151,
Near Gandimaisamma Cross Roads
D.P. Pally, Dundigal Post, Dundigal – Gandimaisamma Mandal
Medchal - Malkajgiri District
Hyderabad 500043, Telangana, India
+91 40-30510999
Responsible person for the safety data sheet (e-mail): sales@xellia.com

Distributor

Xellia Pharmaceuticals
2150 East Lake Cook Road
Buffalo Grove, IL 60089
USA
+1 833 657 3519

1.4. Emergency telephone number

Poison Control Center (USA): +1 877 800 5553
CHEMTREC (USA Transportation): +1 800 424 9300
CANUTREC (Canadian Transportation): +1 613 996 6666
UN #: <http://apps.who.int/poisoncentres/>

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Acute Toxicity – Category 3 (oral); Carcinogenicity – Category 2; Reproductive toxicity – Category 2; Specific Target Organ Toxicity (Repeated Exposure) – Category 2; Hazardous to the aquatic environment, acute hazard – Category 1; Hazardous to the aquatic environment, long-term hazard – Category 3

2.2. Label elements



WARNING!

H301: Toxic if swallowed.
H351: Suspected of causing cancer.

H361: Suspected of damaging fertility or the unborn child.

H373: Causes damage to organs through prolonged or repeated exposure.
H400: Very toxic to aquatic life.
H412: Harmful to aquatic life with long lasting effects
P203: Obtain, read and follow all safety instructions before use.
P260: Do not breathe dust/fume/gas/mist/vapors/spray.
P264: Wash hands thoroughly after handling.
P270: Do not eat, drink or smoke when using this product.

P273: Avoid release to the environment.
P280: Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.
P301+P316: IF SWALLOWED: Get emergency medical help immediately.
P318: if exposed or concerned, get medical advice.
P319: Get medical help if you feel unwell.
P330: Rinse mouth.
P405: Store locked up.
P501: Dispose of contents/container appropriately per local regulation.

2.3. Other hazards:

PBT/vPvB: The substance is not considered PBT/vPvB according to criteria in Annex XIII, neither has properties of endocrine disruption.

SECTION 3: Composition/information on ingredients

3.1. Substances:

Active component	CAS #	EC/List #
Voriconazole	137234-62-9	629-701-5

REACH reg. #: Not registered, exempted

Comments: Not Applicable.

SECTION 4: First Aid Measures

4.1. Description of first aid measures

Eye contact: Flush eyes for 15 minutes with plenty of water. Get medical attention immediately.
Skin contact: Remove contaminated clothing and clean before reuse. Wash all exposed areas of skin with plenty of soap and water. Get medical attention if irritation or rash develops.
Ingestion: Do not induce vomiting. Call a physician or poison control center. Do not give anything by mouth to an unconscious person. Immediately transport to a medical care facility and see a physician.
Inhalation: Move individual to fresh air. Get medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance (mouth-to-mouth) and call a physician immediately.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None

4.3. Indication of any immediate medical attention and special treatment needed

In case of discomfort or unconsciousness: Show this safety data sheet to a physician or emergency center, treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Water, carbon dioxide, dry chemical, foam, or other alternatives.

5.2. Special hazards arising from the substance or mixture

General hazards:	May be combustible at high temperature. Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products:	Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, and chlorides.
Unsuitable extinguishing media:	None
Specific methods:	Not available

5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment, and emergency procedures

Wear personal protective equipment to avoid exposure – see section 8. Avoid generation of dust.

6.2. Environmental precautions

Water spill:	Do not empty into drains.
Land spill:	Vacuum material with appropriate dust collection in place. Be aware of potential for dust explosion when using electrical equipment. If a vacuum is not available, lightly mist material and remove by sweeping or wet wiping. Wear appropriate equipment including eye protection, to avoid exposure.
Release notes:	If the spill could potentially enter any waterway, including intermittent dry creeks, contact the local authorities.

6.3. Methods and materials for containment and cleaning up

Contain dry material by lightly misting with water, followed by sweeping carefully so as not to generate dust, or vacuuming. Ensure the vacuum is fitted with an appropriate dust filter so dust is not re-introduced into the air. Be aware of the potential for dust explosion when using electrical equipment.

6.4. Reference to other sections

See section 1 for emergency contact information, section 8 for personal protective equipment details, and section 13 for disposal information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

For large quantities:	Engineering controls are recommended to ensure adequate ventilation such that exposures do not exceed TWA for an eight-hour exposure. With adequate ventilation, respiratory protection may not be needed. In the absence of adequate ventilation, suitable respiratory protection is required. The need for additional personal protective equipment including respirators, eye and skin protection should be based on a job-specific risk
------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

assessment. Additional personal protective equipment may include chemical-resistant gloves and body covering, goggles, and face shield. Adequate eye protection is always required.

For small quantities: Keep dry and away from sources of ignition. Keep the container tightly closed when not in use.

Work hygienic practices: Facilities storing or using this material should be equipped with an emergency eyewash and safety shower. Good personal hygiene practices should always be followed.

7.2. Conditions for safe storage, including any incompatibilities

Store securely, inaccessible for unauthorized persons. Keep dry and away from sources of ignition. Vials should be stored at 20°C – 25°C (68°F – 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) in original, unopened package or container.

7.3. Specific end use(s)

See section 1.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

OEL for the Voriconazole is 0.1 mg/m³

8.2. Exposure controls

Appropriate engineering controls: If dust is generated, provide local exhaust ventilation to control airborne levels.

PERSONAL PROTECTIVE EQUIPMENT:

Eyes and face: Wear safety glasses with side shields or goggles as appropriate when handling this material.

Skin: Chemical resistant gloves (nitrile or latex) and body covering.

Respiratory: Use an approved respirator suitable to provide level of protection required.

Comments: This product may cause kidney and nervous system damage from overexposure to polymyxin B sulfate, based on clinical use as described in the Physicians Desk Reference. Under conditions of overexposure, this product may be hazardous.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state: Powder

Color: White to almost white

Odor: Odorless

Melting point/freezing point: 134°C

Boiling point or initial boiling point and boiling range: Not applicable for solids

Flammability: Can be burned but not classified

Lower and upper explosive limits: Not applicable for solids

Flash point: Not applicable for solids

Auto-ignition temperature: Not measured

Decomposition temperature: Not measured

pH: Not measured

Kinematic viscosity: Not applicable for solids

Solubility: 0.0978 g/l in water

Partition coefficient n-octanol/water (log value): Not measured

Vapor pressure: Not applicable for solids
Density and/or relative density: Not measured
Relative vapor density: Not applicable for solids
Particle characteristics: Not measured

9.2. Other information:

Not available.

SECTION 10: Stability and reactivity

10.1. Reactivity

No data available.

10.2. Chemical stability

Stable under recommended storage conditions.

10.3. Possibility of hazardous reactions

Hazardous polymerization has not been reported.

10.4. Conditions to avoid

Incompatible materials, dust generation, excess heat, alkaline materials, strong oxidants, exposure to moist air or water.

10.5. Incompatible materials

Strong oxidants, moisture.

10.6. Hazardous decomposition products

Nitrogen oxides, carbon monoxide, and carbon dioxide.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute dermal LD50: No information available

Acute oral LD50: No information available

Acute inhalation LC50: No information available

Based on available data, the classification criteria are not met.

Eye effects: Based on available data, the classification criteria are not met.

Skin effects: Based on available data, the classification criteria are not met.

Sensitization: Based on available data, the classification criteria are not met.

Target organ: Transient elevations in serum aminotransferase levels occur in 11% to 19% of patients on voriconazole. These elevations are usually asymptomatic and self-limited, but approximately 1% of patients require discontinuation of voriconazole because of ALT elevations. Clinically apparent hepatotoxicity is uncommon but may be more frequent than with fluconazole and itraconazole. The injury arises within the first month of therapy and the pattern of serum enzyme elevations has been variable from cholestatic to hepatocellular. Several cases of acute liver failure attributed to voriconazole have been reported. Immunologic features and autoantibodies are uncommon. Recovery upon stopping therapy generally takes 6 to 10 weeks but, in some cases, the time to complete resolution may be prolonged.

Carcinogenicity: Based on available data, the classification criteria are not met.

Listed by IARC: No

Listed by NTP: No

Listed by OSHA: No

Mutagenicity: Based on available data, the classification criteria are not met.

Reproductive effects: Based on available data, the classification criteria are not met.

Teratogenic effects: Based on available data, the classification criteria are not met.

11.2. Information on other hazards

Not available

SECTION 12: Ecological information

12.1. Toxicity

No applicable information found. Releases to the environment should be avoided.

12.2. Persistence and degradability

No applicable information found.

12.3. Bioaccumulative potential

No applicable information found.

12.4. Mobility in soil

No applicable information found.

12.5. Results of PBT and vPvB assessment

The substance is not considered PBT/vPvB according to criteria in Annex XIII.

12.6. Endocrine disrupting properties

No such properties are known to the substance.

12.7. Other adverse effects

The substance is possibly harmful for the aquatic environment, due to its antibiotic properties.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Do not empty into drain. Dispose of any cleanup materials and waste residue according to applicable laws and regulations.

SECTION 14: Transport information

14.1. UN Number or ID number

Not Regulated.

14.2. UN proper shipping name

Not Regulated.

14.3. Transport hazard class(es)

Not Regulated.

14.4. Packing group

Not Regulated.

14.5. Environmental hazards

Not Regulated.

14.6. Special precautions for user

Not Regulated.

14.7. Maritime transport in bulk according to IMO instruments

Not relevant.

USA DOT (DEPARTMENT OF TRANSPORTATION)

Proper Shipping Name: Not regulated.

CANADA TRANSPORT OF DANGEROUS GOODS

Proper Shipping Name: Not regulated.

AIR (ICAO/IATA)

Proper Shipping Name: Not regulated.

VESSEL (IMO/IMDG)

Proper Shipping Name: Not regulated.

EUROPEAN TRANSPORTATION:

ADR/RID HAZARD CLASSIFICATION: Not Regulated.

U.S. CUSTOMS HARMONIZATION NUMBER: Not Available.

SECTION 15: Regulatory information

15.1. Safety, health, and environmental regulations/legislation specific for the substance or mixture

EUROPEAN UNION

Council Directive 94/33/EC of 22 June 1994 on the protection of young people at work:

Must not be used by persons under 18 years of age.

Council Directive 92/85/EEC of 19 October 1992 on the introduction of measures to encourage improvements in the safety and health at work of pregnant workers and workers who have recently given birth or are breastfeeding:

The employer shall assess the working conditions and, if there is any risk to the safety or health and any effects on the pregnancy or breastfeeding of workers, take the necessary measures to adjust the working conditions.

Implementation of directive 2001/82/EC of the European Parliament and of the council of 6 November 2001 in the Community code relating to veterinary medical products:

Denmark: The Danish Medicines Agency (Lægemiddelstyrelsen) must be notified that this substance is produced, imported, exported, stored, sold, delivered, packed, possessed or in other ways handled in Denmark (Bekendtgørelse nr. 1226 af 7 December 2005 om omgang med visse stoffer og produkter hvis indhold kan anvendes som lægemidler til dyr.).

For other countries: Please contact national authorities regarding notification of the substance.

UNITED STATES FEDERAL REGULATIONS

Superfund Amendments and Reauthorization Act (SARA) Title III 311/312 hazard categories:

Fire: No **Pressure generating:** No **Reactivity:** No **Acute:** No **Chronic:** No

313 Reportable Ingredients: Not Listed

Title III notes:

Comprehensive Response, Compensation, and Liability Act (CERCLA)

CERCLA RQ: Not listed

Toxic Substances Control Act (TSCA)

TSCA Regulatory: Exempt

National Response Center: US Coast Guard National Center Response Telephone
+1 800 424 8802.

UNITED STATES STATE REGULATIONS

California Proposition 65: This product does not contain chemicals known to the State of California to cause cancer and birth defects or other reproductive harm.

CANADA

Workplace Hazardous Material Information System (WHMIS) hazard symbol and classification

WHMIS Controlled: Not regulated.

Canadian Environmental Protection Act: Not listed

15.2. Chemical safety assessment

No CSR is compiled because the substance is exempted.

SECTION 16: Other information'

Reason for issue: Update to include 2020/878 EU Commission regulation.

Contact Information: See Section 1.

Revision summary: Third issue

Disclaimer: Information given herein is offered in good faith as accurate, but without guarantee. Conditions of use and suitability of the product for uses are beyond our control; all risks of use of the product are therefore assumed by the user. Nothing is intended as a recommendation for uses that infringe valid patents or as extending license under valid patents. Appropriate warnings and safe handling procedures should be provided to handlers and users.
